LAM

LAM Week

LAM Week

Welcome Message

Together with the LAM foundation, we welcome you the Lymphangioleiomyomatosis (LAM) week at the ATS.  LAM is a rare neoplastic disease that results in progressive cystic lung disease.  It primarily affects women of childbearing age and can occur as a sporadic disease or can be associated with tuberous sclerosis complex (TSC).  Mutations in TSC1 and TSC2 (usually TSC2) have been described in a majority of patients with sporadic LAM.  Presenting symptoms include dyspnea, cough, hemoptysis, spontaneous pneumothorax, abdominal tumors and chylous fluid accumulation.  The diagnosis typically requires a surgical lung biopsy for confirmation, however, in the appropriate clinical setting, a diagnosis can be established based on radiographic (HRCT scan) features of a typical distribution of cysts in both lungs.  LAM is characterized by immunohistochemical reactivity to HMB-45 staining.

Over the last few decades, there has been substantial progress in the understanding of the pathophysiology of LAM.  This has focused on the inappropriate activation of mammalian target of rapamycin (mTOR) signaling.  The inhibition of this pathway is the basis of therapeutic targets.  Drugs such as sirolimus and everolimus have been shown to slow the rate of disease progression.

With our PAR partner, the LAM foundation, we hope to provide resources for clinicians, researchers and patients and to continue to support research pursuits in LAM.

 

Ganesh Raghu, M.D.,FCCP,FACP

Ganesh Raghu, M.D.,FCCP,FACP
Adjunct Professor, Laboratory Medicine
Division of Pulmonary and Critical Care Medicine
Director, CENTER Interstitial Lung Disease (ILD), UW Medicine
ILD/Sarcoidosis/Pulmonary Fibrosis Program
Co-Director, Scleroderma Clinic, UW Medicine

Lawrence Ho, MD

Lawrence Ho, MD
Clinical Assistant Professor
Division of Pulmonary and Critical Care Medicine
CENTER for Interstitial Lung Disease (ILD)
University of Washington

Mary Harbaugh, PhD

Mary Harbaugh, PhD
Board Member
The LAM Foundation
Member, ATS Public Advisory Roundtable

 

ATS LAM PARTNER
The LAM Foundation

image

The LAM Foundation urgently seeks safe and effective treatments, and ultimately a cure, for lymphangioleiomyomatosis (LAM) through advocacy and the funding of promising research. We are dedicated to serving the scientific, medical and patient communities by offering information, resources and a worldwide network of hope and support.